Novartis….
In recent times Novartis has been restructuring and it says it is now focusing on four key therapeutic areas, none of which is Ophthalmology.
As you stated, Beovue has been a bit of a disaster for Novartis since it launched in late 2019. Sales revenues from Beovue aren’t even mentioned.
Adding to the company's problems in ophthalmology, Lucentis biosimilars have been coming thick and fast since patent expiry with, I think, five biosimilars now approved in Europe.
Lucentis sales in FY2021 were US$2.16 bn. In FY 2023, sales had fallen to US$1.475 bn.
Early last year Novartis announced that it was looking to trim its ophthalmology portfolio and sell off some of its assets. In June it announced that it had sold “front of eye” ophthalmology assets to Bausch and Lomb for up to US$2.5bn.
But the assets sold didn’t include Lucentis. According to a Bloomberg Report “Novartis is keen to hold onto Lucentis (ranibizumab).”
It certainly makes me wonder why.
Novartis Explores Sale of Certain Ophthalmology Assets | BioSpace
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy | Novartis
Novartis…. In recent times Novartis has been restructuring and...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.5¢ |
Change
-0.025(3.91%) |
Mkt cap ! $407.6M | |||
| Open | High | Low | Value | Volume |
| 63.5¢ | 63.5¢ | 61.0¢ | $222.9K | 361.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11473 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 63.0¢ | 90766 | 2 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
61.5¢ |
Change
-0.025 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 62.0¢ | 62.5¢ | 61.0¢ | 101391 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| OPT (ASX) Chart |